According to DelveInsight’s latest analysis, Nipocalimab is expected to capture meaningful market share across both prevalent ...

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...

SCOUT-HCM demonstrated the superiority of Camzyos on the primary endpoint and multiple secondary endpointsThe overall safety results in this study were consistent with the established safety profile ...

Data is from comprehensive review of hospital charges and all-payer claims over five years - - Preventable complications such as amputation and conduit infection increased initial hospital charges by ...

CHICAGO, Jan. 15, 2026 /PRNewswire/ -- The National Certification Corporation (NCC) is pleased to announce the release of their newest Monograph -- Fetal Assessment and Safe Care During Labor. This ...

Research led by the SickKids Research Institute in Toronto and the University of Pennsylvania, has found that immune-related ...

CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for ...

A diet high in fat is one of the strongest contributors to liver cancer risk. New research from MIT sheds light on why this ...

U.S. FILSPARI reaches all-time highs of 908 new PSFs and net product sales of approximately $103 million in 4Q 2025Company ...